Jean-Christophe Tellier, UCB CEO (Jasper Jacobs/Belga/Sipa USA/Sipa via AP Images)
UCB enters gene therapy space, inking license agreement for epilepsy and neurodegeneration research
UCB may not have any gene therapy candidates on the market or publicly in its pipeline, but that hasn’t stopped the pharma from inking a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
